Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. CKD Corporation
  6. Summary
    6407   JP3346800000

CKD CORPORATION

(6407)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
2462 2452 2451 2477 2501 Last
320200 345900 220000 306600 274300 Volume
-0.12% -0.41% -0.04% +1.06% +0.97% Change
Financials
Sales 2021 104 B 943 M 943 M
Net income 2021 4 660 M 42,1 M 42,1 M
Net cash position 2021 742 M 6,70 M 6,70 M
P/E ratio 2021 35,2x
Yield 2021 0,64%
Sales 2022 122 B 1 103 M 1 103 M
Net income 2022 8 780 M 79,3 M 79,3 M
Net cash position 2022 14 242 M 129 M 129 M
P/E ratio 2022 18,9x
Yield 2022 1,49%
Capitalization 167 B 1 516 M 1 505 M
EV / Sales 2021 1,59x
EV / Sales 2022 1,25x
Nbr of Employees 4 470
Free-Float 82,4%
More Financials
Company
CKD Corporation is engaged in the manufacture and sale of automatic machinery and equipment. The Automatic Machinery segment offers automatic packaging systems, image processing inspection systems, lithium-ion battery manufacturing systems, three-dimensional solder printing inspection machines, lighting manufacturing systems and capacitor manufacturing systems. The Machinery segment offers index units, direct drive... 
More about the company
Ratings of CKD Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CKD CORPORATION
05/18NOVO NORDISK A/Sá : Ziltivekimab Cuts Inflammation in Mid-Stage Kidney Disease S..
MT
05/04PRESS RELEASE : Evotec and the GCKD study enter into strategic collaboration to ..
DJ
05/04AstraZeneca's Farxiga Gets U.S. FDA Approval as Chronic-Kidney-Disease Treatm..
DJ
05/03ASTRAZENECAá : Farxiga Drug Gets FDA Approval as Treatment for Chronic Kidney Di..
MT
05/02ASTRAZENECAá : Farxiga Treatment for Chronic Kidney Disease Gets US FDA Approval
MT
04/27RESVERLOGIXá : Says Apabetalone Demonstrates Medical First in Patients with Chro..
MT
04/21RELIQ HEALTH TECHNOLOGIESá : Details Two New Contracts with US Nephrology Clinic..
MT
03/31Otsuka Partner Akebia Therapeutics Submits Drug Application to US FDA for Chr..
MT
03/30CKD CORPORATION : Ex-dividend day for final dividend
FA
03/01PRESS RELEASE : Evotec and Chinook Therapeutics enter into strategic collaborati..
DJ
02/24RELIQ HEALTH TECHNOLOGIESá : Up 6% As Signs Contract with US Nephrology Clinic t..
MT
2020CKD CORPORATION : Ex-dividend day for interim dividend
FA
2020ASTRAZENECAá : diabetes drug improves survival in kidney disease patients study ..
RE
2020Astrazeneca says farxiga reduced death from any cause by 31% in patients with..
RE
2020AstraZeneca diabetes drug shows promise in severe kidney condition
RE
More news
News in other languages on CKD CORPORATION
05/04FDA gibt Farxiga von Astrazeneca für chronische Nierenleiden frei
04/30Vifor-Gemeinschaftsunternehmen VFMCRP erreicht Ziele in Studie mit Velphoro
02/08Roche erhält für Elecsys GDF-15-Test 'Breakthrough Device'-Status von FDA
2020Bayer will neues Nierenmedikament für Diabetiker schnell auf den Markt bringe..
2020Vifor Pharma sichert sich über Lizenzabkommen mit Cara Therapeutics US-Zugang
More news
Chart CKD CORPORATION
Duration : Period :
CKD Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CKD CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 2 835,56 JPY
Last Close Price 2 501,00 JPY
Spread / Highest target 35,9%
Spread / Average Target 13,4%
Spread / Lowest Target -29,2%
EPS Revisions
Managers and Directors
NameTitle
Kazunori Kajimoto President & Representative Director
Junichi Kagawa Independent Outside Director
Noriko Asai Independent Outside Director
Kazumasa Uemura Independent Outside Director
Shinji Yuhara Director & General Manager-Sales
Sector and Competitors
1st jan.Capitalization (M$)
CKD CORPORATION13.27%1 499
NORDSON CORPORATION10.98%12 960
WUHAN GUIDE INFRARED CO., LTD.-15.80%9 513
SUZHOU MAXWELL TECHNOLOGIES CO., LTD.7.37%6 824
VALMET OYJ46.88%6 219
HAITIAN INTERNATIONAL HOLDINGS LIMITED-2.99%5 449